A MISC 05451 Academy of Next Wave Investigators banner scaled

Next Wave Academy Applications

Applications Open: September 14, 2022
Applications Close: December 16, 2022
Applicant Notifications: January 20, 2023

The Next Wave of Clinical Investigators activity is a unique opportunity for young clinical investigators to engage with international thought leaders in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in an intimate setting that educates these young investigators on tactics to expand their clinical research and impact the future of patient care.

Selected young investigators will be provided:
  • Registration at an in-person 1.5-day conference featuring sessions with leading CLL and NHL faculty on professional development as well as networking opportunities
  • Travel to attend the conference and 2 nights’ accommodation at the venue hotel
  • Matching with a mentor in their area of interest for regular touch points throughout the year
  • Quarterly virtual meetings on professional development topics
  • Reception to be held in-person at the American Society of Hematology (ASH) 2023 Annual Meeting and Exposition

A limited number of participants from industry will be in attendance both Friday, April 28 and Saturday, April 29. Interaction between industry representatives and the academy attendees will be limited.

Top 5 abstract submissions will also receive:

  • An opportunity to present a 10-minute oral presentation during the conference
  • Recognition as a top performer in the academy
    • 1 additional applicant will be recognized for having the top presentation skills
Eligibility:
The top 25 applicants will be invited to participate in the Next Wave Academy.
  • Applicants must be in their final 2 years of a fellowship program or within 5 years post-fellowship.
  • Applicants must be US-based (MDs, MD/PhDs, and DOs) and currently employed in active patient care and patient-oriented clinical in CLL or NHL or being trained at an institution in the United States.
  • Applicants must not be employed by a commercial pharmaceutical, biotech, or other biomedical company.
  • Selected applicants must commit to actively participating in the program for the full year of activities.
Ineligibility:
  • Individuals residing or working outside the United States at the time of application are not eligible.
  • Individuals who are not participating in patient-oriented clinical research (e.g. preclinical research)
  • Individuals who have received independent research funding at the time of application
  • PhD only research fellows
Application:
Applicants must complete the online application, including the materials below:
  • Recommendation letter from fellowship program director or clinical investigator in the field of CLL or NHL
  • NIH Biosketch preferred (maximum 5 pages) or CV
  • Brief video (2 minutes or less) explaining why they want to participate in the Next Wave Academy, demonstrating the applicants’ presentation skills and detailing their goals for the 1-year mentoring program
  • Submission of an abstract for the conference
    • The abstract should be a summary of a research plan for a future study
Selection process:
The Steering Committee will review all applications. Applicants will be evaluated on the following criteria:
  • Contribution to science: clear commitment to an academic oncology career through publication and project efforts, and training to date
  • Clear goals: specific and achievable aims for the mentoring program
  • Abstract quality: submitted abstract will be evaluated using the following criteria:
    • Scientific importance: will this research make a difference in diagnosis, treatment, or quality of patient care?
    • Quality of research: is the hypothesis feasible and will the stated methodology enable this research to be completed in a meaningful way?
    • Enhance knowledge: will the research improve our knowledge about the disease or treatment
    • Does the research answer a question that needs to be answered or provide new findings that may change the way we diagnose or treat a condition?
    • Overall presentation of abstract: is the abstract informative and thoughtfully written; does it outline the question to be addressed; and is the research proposed able to provide an answer?

Questions? Please contact bunyasaranand@bioascend.com